The purpose of the Career Developmental Program (CDP) of the RPCI-UPCI Ovarian Cancer SPORE is to support the career development of junior researchers in translational ovarian cancer research. The target population for the program is outstanding entry-level (i.e. Assistant Professor) scientific and clinical faculty, but in some cases may include senior postdoctoral or clinical fellows with exceptional potential for independent research careers, or established investigators wishing to refocus their careers on translational ovarian cancer research. A secondary goal of the CDP is to promote the diversity of ovarian cancer researchers, by encouraging the recruitment of outstanding individuals from underrepresented groups. The CDP will be supported both by RPCI-UPCI Ovarian Cancer SPORE funds and matching institutional funds from RPCI and UPCI. The CDP serves as a structured mechanism for identifying outstanding candidates through an open and competitive application and review process, and matching the resulting awardees with experienced mentors. The CDP Leaders will convene a NIH format study section and assign NIH R21-type applications to two scientific and one patient advocate reviewers. Review results will be summarized in the Administrative Core and submitted to the Internal Advisory Board for recommendations for funding. Successful applications will be funded at the level of $50,000 per year for of two years (total award $100,000). We anticipate to fund three to five awards per year depending on the funding year. CDP awardees will be provided full access to the RPCI-UPCI Ovarian Cancer SPORE Core resources, including tissue specimens and statistical support. The CDP will directly facilitate career development through: i) a constructive proposal review by the RPCI-UPCI Ovarian Cancer SPORE Executive Committee and Internal Advisory Board, which are composed of talented investigators with expertise in basic, clinical, and population-based research, ii) research training with a mentor chosen from among a diverse faculty with broad expertise in academic career development, and iii) access to development/enrichment programs, including ovarian cancer disease site research group meetings, periodic SPORE meetings, seminar series, and RPCI-UPCI Ovarian Cancer SPORE annual retreats. In summary, the CDP provides a vital mechanism for the development of the next generation of translational ovarian cancer researchers at RPCI and UPCI.
The ultimate long-term objective of CDP is to develop novel ways to reduce the burden of ovarian cancer, through translational, clinical, and population-based research. A prerequisite for achieving this objective is a continual influx of newly independent researchers with interest, experience, and expertise in ovarian cancer. The Career Development Program of the RPCI-UPCI Ovarian Cancer SPORE will support the career development of the next generation of translational ovarian cancer researchers.
|Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320|
|Wang, Zehua; Yang, Bo; Zhang, Min et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33:706-720.e9|
|Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035|
|Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182|
|Shenoy, Gautam N; Loyall, Jenni; Berenson, Charles S et al. (2018) Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. J Immunol 201:3750-3758|
|Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430|
|Wang, Yue; Wang, Zehua; Xu, Jieni et al. (2018) Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun 9:3192|
|Minlikeeva, Albina N; Moysich, Kirsten B; Mayor, Paul C et al. (2018) Anthropometric characteristics and ovarian cancer risk and survival. Cancer Causes Control 29:201-212|
|Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472|
|Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33|
Showing the most recent 10 out of 128 publications